CN112166107A - 4-苯基噻唑衍生物的晶型及其制备方法 - Google Patents

4-苯基噻唑衍生物的晶型及其制备方法 Download PDF

Info

Publication number
CN112166107A
CN112166107A CN201980031138.9A CN201980031138A CN112166107A CN 112166107 A CN112166107 A CN 112166107A CN 201980031138 A CN201980031138 A CN 201980031138A CN 112166107 A CN112166107 A CN 112166107A
Authority
CN
China
Prior art keywords
degrees
solvent
ray powder
crystal form
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980031138.9A
Other languages
English (en)
Other versions
CN112166107B (zh
Inventor
易仕东
宫正
王天明
杨成喜
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Original Assignee
Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Pharmaceutical Research Institute Co Ltd filed Critical Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Publication of CN112166107A publication Critical patent/CN112166107A/zh
Application granted granted Critical
Publication of CN112166107B publication Critical patent/CN112166107B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及4‑苯基噻唑衍生物的晶型、包含其的药物组合物、制备方法以及所述晶型在制备用于治疗血小板减少症的药物中的用途。
Figure DDA0002767303510000011

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980031138.9A 2018-06-08 2019-05-29 4-苯基噻唑衍生物的晶型及其制备方法 Active CN112166107B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810585583 2018-06-08
CN2018105855837 2018-06-08
PCT/CN2019/088959 WO2019233328A1 (zh) 2018-06-08 2019-05-29 4-苯基噻唑衍生物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN112166107A true CN112166107A (zh) 2021-01-01
CN112166107B CN112166107B (zh) 2023-10-27

Family

ID=68769724

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031138.9A Active CN112166107B (zh) 2018-06-08 2019-05-29 4-苯基噻唑衍生物的晶型及其制备方法

Country Status (6)

Country Link
US (1) US11174234B2 (zh)
EP (1) EP3808736B1 (zh)
JP (2) JP2021525230A (zh)
CN (1) CN112166107B (zh)
ES (1) ES2953320T3 (zh)
WO (1) WO2019233328A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809008A (zh) * 2007-07-31 2010-08-18 盐野义制药株式会社 含有具血小板生成素受体激动作用的光学活性化合物的药物组合物及其中间体
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
CN106083759A (zh) * 2016-06-15 2016-11-09 上海丸全化学科技有限公司 一种芦曲泊帕的全新合成工艺
CN109311831A (zh) * 2017-02-14 2019-02-05 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US20150148385A1 (en) 2012-06-29 2015-05-28 Shionogi & Co., Ltd. Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity
CN109970678B (zh) 2017-12-28 2024-03-08 四川科伦药物研究院有限公司 4-苯基噻唑衍生物无定形及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809008A (zh) * 2007-07-31 2010-08-18 盐野义制药株式会社 含有具血小板生成素受体激动作用的光学活性化合物的药物组合物及其中间体
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
CN106083759A (zh) * 2016-06-15 2016-11-09 上海丸全化学科技有限公司 一种芦曲泊帕的全新合成工艺
CN109311831A (zh) * 2017-02-14 2019-02-05 四川科伦药物研究院有限公司 4-苯基噻唑衍生物的晶型及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
潘卫三: "《工业药剂学》", 中国医药科技出版社 *

Also Published As

Publication number Publication date
JP2021525230A (ja) 2021-09-24
JP2024038059A (ja) 2024-03-19
WO2019233328A1 (zh) 2019-12-12
EP3808736A1 (en) 2021-04-21
EP3808736A4 (en) 2022-02-09
ES2953320T3 (es) 2023-11-10
US20210269410A1 (en) 2021-09-02
US11174234B2 (en) 2021-11-16
EP3808736B1 (en) 2023-08-09
CN112166107B (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
KR101917557B1 (ko) 3,5-2치환 벤젠알키닐 화합물의 결정
KR20170137916A (ko) 우라실 화합물의 신규 결정
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
CN114206878B (zh) 乌帕替尼的晶型及其制备方法和用途
CN108884080A (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
US11434194B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
EP3159349B1 (en) Lobaplatin crystal, preparation method and pharmaceutical application
CN109311831B (zh) 4-苯基噻唑衍生物的晶型及其制备方法
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
TW202039511A (zh) Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物
CN112166107A (zh) 4-苯基噻唑衍生物的晶型及其制备方法
CN113631542B (zh) 一种芳香族化合物的固体形式及其制备方法
CN112142737B (zh) 一种治疗精神分裂症药物盐酸盐的固体形式
CN112105622B (zh) 丙戊酸磷脂衍生物的晶型及其制备方法
CN112262138A (zh) 盐形式
US20180258069A1 (en) New crystal of piperazine compound
CN103588695B (zh) 一种结晶形式的奥拉西坦化合物及其制备方法
CN114685512B (zh) 一种伊布替尼-烟酸共晶及其制备方法
US11958860B2 (en) Crystal form of compound, and preparation method therefor and use thereof
WO2014147641A2 (en) Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof
CN111918869A (zh) 甘草酸衍生物的结晶、其结晶组合物、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant